JNJ

188.98

-0.04%↓

ABT

123.58

-0.84%↓

TMO

568.01

+2.1%↑

ISRG

534.39

+0.84%↑

DHR

215.62

+0.34%↑

JNJ

188.98

-0.04%↓

ABT

123.58

-0.84%↓

TMO

568.01

+2.1%↑

ISRG

534.39

+0.84%↑

DHR

215.62

+0.34%↑

JNJ

188.98

-0.04%↓

ABT

123.58

-0.84%↓

TMO

568.01

+2.1%↑

ISRG

534.39

+0.84%↑

DHR

215.62

+0.34%↑

JNJ

188.98

-0.04%↓

ABT

123.58

-0.84%↓

TMO

568.01

+2.1%↑

ISRG

534.39

+0.84%↑

DHR

215.62

+0.34%↑

JNJ

188.98

-0.04%↓

ABT

123.58

-0.84%↓

TMO

568.01

+2.1%↑

ISRG

534.39

+0.84%↑

DHR

215.62

+0.34%↑

Начало・Списък с акции・Ionis Pharmaceuticals Inc

Ionis Pharmaceuticals Inc

Затворен

СекторЗдравеопазване

74.3 0.15

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

73.76

Максимум

75.4

Ключови измерители
By Trading Economics
Приходи	270M 124M
Продажби	320M 452M
Марж на печалбата	27.331
Служители	1,069
EBITDA	294M 150M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+8.94% upside

Пазарни показатели
By TradingEconomics
Пазарна капитализация	5.1B 12B
Предишно отваряне	74.15
Предишно затваряне	74.3

Техническа оценка

By Trading Central

Увереност

Neutral Evidence

29.78 / 33.645 Подкрепа & съпротива

Ionis Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

31.10.2025 г., 17:40 ч. UTC

Придобивния, сливания и поглъщания

Orange to Buy Lorca's 50% Stake in MasOrange for $4.9 Billion

31.10.2025 г., 23:09 ч. UTC

Печалби

Review & Preview: October Surprise -- Barrons.com

31.10.2025 г., 22:44 ч. UTC

Придобивния, сливания и поглъщания

Pfizer Sues Seeking to Block Novo Nordisk's Effort to Undo Weight-Loss Drug Deal -- WSJ

31.10.2025 г., 21:25 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Pfizer Says Novo Nordisk's Metsera Bid Won't Pass Antitrust Laws -- Market Talk

31.10.2025 г., 21:20 ч. UTC

Придобивния, сливания и поглъщания

Pfizer Sues Seeking to Block Novo Nordisk's Effort to Undo Weight-Loss Drug Deal -- Update

31.10.2025 г., 21:12 ч. UTC

Придобивния, сливания и поглъщания

Pfizer Sues Metsera, Novo Nordisk, Claiming Novo Nordisk Takeover Offer Isn't Superior -- WSJ

31.10.2025 г., 21:12 ч. UTC

Придобивния, сливания и поглъщания

Pfizer Sues Seeking to Block Novo Nordisk's Effort to Undo Weight-Loss Drug Deal -- WSJ

31.10.2025 г., 21:12 ч. UTC

Придобивния, сливания и поглъщания

Pfizer Seeks Order Blocking Metsera From Terminating Its Merger Deal With Pfizer -- WSJ

31.10.2025 г., 20:51 ч. UTC

Придобивния, сливания и поглъщания

Another Rare-Earth Stock Jumps on Government Deal -- Barrons.com

31.10.2025 г., 20:50 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

31.10.2025 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

31.10.2025 г., 20:50 ч. UTC

Пазарно говорене

Печалби

Auto & Transport Roundup: Market Talk

31.10.2025 г., 20:46 ч. UTC

Придобивния, сливания и поглъщания

Pfizer: Files Lawsuit Against Metsera and Its Directors and Novo Nordisk for Breach of Merger Agreement

31.10.2025 г., 20:22 ч. UTC

Печалби

Amazon Stock Hits New Record. What Was So Good in Its Earnings Report. -- Barrons.com

31.10.2025 г., 20:02 ч. UTC

Печалби

Meta Faces a Sudden Reckoning. How Big Tech Earnings Are Reshaping the AI Race. -- Barrons.com

31.10.2025 г., 19:55 ч. UTC

Пазарно говорене

Crude Futures Fall for Third Straight Month -- Market Talk

31.10.2025 г., 19:54 ч. UTC

Придобивния, сливания и поглъщания

Pfizer: FTC Granted Early Termination of Waiting Period >PFE

31.10.2025 г., 19:54 ч. UTC

Придобивния, сливания и поглъщания

Pfizer: Receives Early Clearance From FTC for Metsera Acquisition

31.10.2025 г., 19:26 ч. UTC

Пазарно говорене

U.S. Natural Gas Rises on Winter Outlook, Strong LNG -- Market Talk

31.10.2025 г., 18:30 ч. UTC

Печалби

These Stocks Are Moving the Most Today: Amazon, Nvidia, Apple, Netflix, Exxon, DexCom, Coinbase, Reddit, Newell Brands, and More -- Barrons.com

31.10.2025 г., 18:23 ч. UTC

Пазарно говорене

Gold Edges Lower for the Day, Closes October Positive -- Market Talk

31.10.2025 г., 18:09 ч. UTC

Печалби

Bank of America Has a Game Plan to Catch Up to Its Peers. It's Time to Buy the Stock. -- Barrons.com

31.10.2025 г., 18:08 ч. UTC

Печалби

Bank of America Has a Game Plan to Catch Up to Its Peers. It's Time to Buy the Stock. -- Barrons.com

31.10.2025 г., 17:36 ч. UTC

Пазарно говорене

Grain Futures Shrug Off Stronger Dollar -- Market Talk

31.10.2025 г., 17:31 ч. UTC

Пазарно говорене

U.S. Oil Rig Count Falls, Natural Gas Rig Count Rises -- Market Talk

31.10.2025 г., 17:16 ч. UTC

Придобивния, сливания и поглъщания

Orange: Acquisition Likely Completed in First Half Next Year

31.10.2025 г., 17:15 ч. UTC

Придобивния, сливания и поглъщания

Orange: Agreement Set to Be Signed By Year-Out

31.10.2025 г., 17:14 ч. UTC

Придобивния, сливания и поглъщания

Orange: Acquisition Will Strengthen Position in Spain

31.10.2025 г., 17:13 ч. UTC

Придобивния, сливания и поглъщания

Orange Will Be Sole Owner of Spain's MasOrange Following Acquisition of Lorca's Stake

31.10.2025 г., 17:12 ч. UTC

Придобивния, сливания и поглъщания

Orange Reaches Deal to Buy Lorca's 50% Stake in MasOrange for EUR4.25B

Сравнение с други в отрасъла

Ценова промяна

Ionis Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

8.94% нагоре

12-месечна прогноза

Среден 80.8 USD 8.94%

Висок 100 USD

Нисък 46 USD

Според 21 анализатори от Wall Street, предложили 12-месечна ценова цел за Ionis Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

21 ratings

Купи

Задържане

Продай

Според 21 анализатори, дали борсови рейтинги на Ionis Pharmaceuticals Inc през последните 3 месеца.

Техническа оценка

By Trading Central

29.78 / 33.645Подкрепа & съпротива

The bullish and bearish events are balanced.

All events are bullish.

All events are bearish.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Ionis Pharmaceuticals Inc

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.